DP
ALNY icon

DDD Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

DDD Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Sell
694
-195
-22% -$58.8K 0.01% 157
2026
Q1 		$294K Buy
+889
New +$303K 0.02% 115

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DDD Partners's ALNY Position: Q2 2026 in Review

DDD Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 22% in Q2 2026, selling an estimated $58.8K and leaving 694 shares worth $209K. The position accounts for 0.01% of the portfolio, ranked #157.

DDD Partners first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $294K in Q1 2026. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • DDD Partners held 694 shares of Alnylam Pharmaceuticals worth $209K as of Q2 2026.
  • DDD Partners sold 195 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $58.8K.
  • Alnylam Pharmaceuticals made up 0.01% of DDD Partners's portfolio in Q2 2026, its #157 holding.
  • DDD Partners first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • DDD Partners's Alnylam Pharmaceuticals position peaked at $294K in Q1 2026.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on DDD Partners's 13F filing for Q2 2026, filed 5 Aug 2026.